Uptake of buprenorphine treatment for opioid use disorder is highly uneven across the United States
· Medical Xpressedited by Stephanie Baum, reviewed by Andrew Zinin
Stephanie Baum
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
There has been a substantial increase in recent years in the use of a form of primary medication to treat opioid use disorder, according to a Rutgers Health study published in Health Affairs. Researchers have also noted sharp differences in growth trends across the United States.
The first long-acting injectable form of buprenorphine, the most common medication for treating opioid use disorder, was approved by the Food and Drug Administration for use in 2018. As a partial rather than full blocker of the opioid receptor, it blocks the effects of opioid drugs such as heroin or fentanyl and reduces the risk of overdose. Long-acting injectables deliver buprenorphine via a shot, slowly releasing it into the bloodstream over a full month to provide a steady level of medication over time, as opposed to sublingual or oral forms.
The work examined pharmacy prescription claims from 2021 to 2024, including more than 4 billion prescriptions dispensed annually. Researchers explored state-level trends in the volume of long-acting injectable buprenorphine prescriptions, as well as trends in insurance payer type, such as Medicaid, Medicare, commercial or self-pay, and prescriber specialty, such as physicians or advanced practice clinicians.
"The data showed a rapid uptake of long-acting injectable buprenorphine, with the total number of buprenorphine prescriptions in injectable form increasing tenfold from 2021 to 2024," said Stephen Crystal, the director of the Rutgers Center for Health Services Research and a co-author of the study
"This matters because an injectable formulation could be lifesaving for those patients who struggle to stabilize on daily oral medication. Sustained levels of medication, potentially reducing cravings for illicit drugs and assuring protection for a full month, may reduce the risk of overdose, particularly for individuals at high risk, such as those treated for prior overdose or in unstable living situations."
Researchers observed marked increases in prescriptions for patients with Medicaid insurance benefits, the joint federal-state program that provides free or low-cost health coverage to low-income or disabled Americans. Pennsylvania, Louisiana, Alaska and Ohio had the highest rates of long-acting injectable prescriptions, possibly because of policies in their Medicaid plans that made this type of buprenorphine more accessible, according to researchers.
While overall prescription increases were observed, researchers noted significant differences in growth trends across states. In some states, less than 1% of prescribed buprenorphine was in long-acting injectable form, while in others, close to 13% was prescribed in injectable form by 2024.
"Given the variation across states, it's evident that state-level policy decisions and insurance plan designs have a meaningful impact on expanding access to lifesaving opioid-use disorder treatment," said Arthur Robin Williams, an associate professor at Columbia University and the lead author of the study.
Researchers also found disproportionate increases in long-acting injectable buprenorphine prescriptions among advanced practice clinicians, such as nurse practitioners and physician assistants.
"These findings highlight the crucial role of Medicaid, as well as advanced practice clinicians rather than physicians, in combating the opioid crisis," Crystal said.
Publication details
Health Affairs (2026). DOI: 10.1377/hlthaff.2025.01584
Journal information: Health Affairs
Key medical concepts
Opioids and Opioid Use Disorder (OUD)MedicaidReceptors, Opioid
Clinical categories
Psychiatry Provided by Rutgers University Who's behind this story?
Stephanie Baum
Master's in TESOL from The New School. Passionate about language learning and editing science news on biology and space exploration. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Uptake of buprenorphine treatment for opioid use disorder is highly uneven across the United States (2026, July 7) retrieved 7 July 2026 from https://medicalxpress.com/news/2026-07-uptake-buprenorphine-treatment-opioid-disorder.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.